Literature DB >> 15001589

A novel dysfunctional growth hormone variant (Ile179Met) exhibits a decreased ability to activate the extracellular signal-regulated kinase pathway.

Mark D Lewis1, Martin Horan, David S Millar, Vicky Newsway, Tammy E Easter, Linda Fryklund, John W Gregory, Martin Norin, Cristóbal-Jorge Del Valle, Juan Pedro López-Siguero, Ramón Cañete, Luis Fernando López-Canti, Nieves Díaz-Torrado, Rafael Espino, Angels Ulied, Maurice F Scanlon, Annie M Procter, David N Cooper.   

Abstract

The pituitary-expressed GH1 gene was screened for mutation in a group of 74 children with familial short stature. Two novel mutations were identified: an Ile179Met substitution and a -360A-->G promoter variant. The Ile179Met variant was shown to exhibit a similar degree of resistance to proteolysis as wild-type GH, indicating that the introduction of Met does not cause significant misfolding. Secretion of Ile179Met GH from rat pituitary cells was also similar to that of wild type. Although receptor binding studies failed to show any difference in binding characteristics, molecular modeling studies suggested that the Ile179Met substitution might nevertheless perturb interactions between GH and the GH receptor loop containing the hotspot residue Trp169, thereby affecting signal transduction. The ability of the Ile179Met variant to activate a signal transducer and activator of transcription (STAT) 5-responsive luciferase reporter gene and induce phosphorylation of STAT 5 and ERK was therefore studied. In contrast to its ability to activate STAT 5 normally, activation of ERK by the Ile179Met variant was reduced to half that observed with wild type. Although differential effects on the activation of distinct signaling pathways by a mutant receptor agonist are unprecedented, these findings also suggest that the ERK pathway could play a role in mediating the action of GH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001589     DOI: 10.1210/jc.2003-030652

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Genetic variation at the growth hormone (GH1) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke.

Authors:  Martin Horan; Vicky Newsway; Mark D Lewis; Tammy E Easter; D Aled Rees; Arti Mahto; David S Millar; Annie M Procter; Maurice F Scanlon; Ian B Wilkinson; Ian P Hall; Amanda Wheatley; John Blakey; Philip M W Bath; John R Cockcroft; Michael Krawczak; David N Cooper
Journal:  Hum Genet       Date:  2006-03-30       Impact factor: 4.132

Review 2.  Genetic causes and treatment of isolated growth hormone deficiency-an update.

Authors:  Kyriaki S Alatzoglou; Mehul T Dattani
Journal:  Nat Rev Endocrinol       Date:  2010-10       Impact factor: 43.330

3.  Efficacy of long-term growth hormone therapy in short children with reduced growth hormone biological activity.

Authors:  S Pagani; C Meazza; K Laarej; F Cantoni; M Bozzola
Journal:  J Endocrinol Invest       Date:  2011-04-20       Impact factor: 4.256

Review 4.  Isolated growth hormone deficiency.

Authors:  Libia M Hernández; Phillip D K Lee; Cecilia Camacho-Hübner
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 5.  S179D prolactin: antagonistic agony!

Authors:  Ameae M Walker
Journal:  Mol Cell Endocrinol       Date:  2007-06-28       Impact factor: 4.102

6.  Human growth hormone (GH1) gene polymorphism map in a normal-statured adult population.

Authors:  Cristina Esteban; Laura Audí; Antonio Carrascosa; Mónica Fernández-Cancio; Annalisa Pérez-Arroyo; Angels Ulied; Pilar Andaluz; Rosa Arjona; Marian Albisu; María Clemente; Miquel Gussinyé; Diego Yeste
Journal:  Clin Endocrinol (Oxf)       Date:  2007-02       Impact factor: 3.478

7.  Mass spectrometrical analysis of recombinant human growth hormone (Genotropin(R)) reveals amino acid substitutions in 2% of the expressed protein.

Authors:  Felix Hepner; Edina Cszasar; Elisabeth Roitinger; Gert Lubec
Journal:  Proteome Sci       Date:  2005-02-11       Impact factor: 2.480

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.